![](https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEhiMNcD8BAbV0jFknfJCD_y93w9vOj0_g-VeVxSP1eGXgII0jXo6YgQKrq2X4EQtWhlAiFeqW2ZAA8ScnMNLQIrcjdk0kU7RnSOykJnajVZ8y46C79gt9kng-PLrJ3z3ayb5TZ9/s400/VYlaw.jpg)
U.S. regulators said on Friday they would review whether to take action over Merck & Co Inc's and Schering-Plough Corp's popular cholesterol drug Vytorin after a study showed it was no better than a generic in preventing the build-up of fatty plaque.
The Food and Drug Administration said it had not yet received a final report on the study, called ENHANCE. The agency's review of Vytorin will take about six months after final results are received, the FDA said.
More at Reuters
No comments:
Post a Comment